{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:51:57Z","timestamp":1790139117321,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejpb.2025.114903","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T06:48:43Z","timestamp":1760683723000},"page":"114903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Self-assembled rapamycin prodrug nanoparticles for posterior segment targeting and effective treatment of experimental uveitis"],"prefix":"10.1016","volume":"217","author":[{"given":"Fangming","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuBo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-1701","authenticated-orcid":false,"given":"Hongzhuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4\u20135","key":"10.1016\/j.ejpb.2025.114903_b0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.autrev.2014.01.006","article-title":"Diagnosis and classification of autoimmune uveitis","volume":"13","author":"Selmi","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejpb.2025.114903_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152692","article-title":"Pathogenesis and targets in uveitis","volume":"72","author":"Ramanan","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejpb.2025.114903_b0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2018.02.019","article-title":"Autoimmunity, Autoinflammation, and Infection in Uveitis","volume":"189","author":"Forrester","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2025.114903_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100803","article-title":"Interactions of the choroid, Bruch's membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier","volume":"76","author":"Fields","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2025.114903_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109565","article-title":"T cells in ocular autoimmune uveitis: Pathways and therapeutic approaches","volume":"114","author":"Zhang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2025.114903_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106888","article-title":"Dysregulated Th17\/Treg cell axis is correlated with local and systemic immune response in human intermediate uveitis","volume":"268","author":"Saini","year":"2024","journal-title":"Immunol. Lett."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114903_b0035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00281-014-0433-9","article-title":"Autoimmune and autoinflammatory mechanisms in uveitis","volume":"36","author":"Lee","year":"2014","journal-title":"Semin. Immunopathol."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114903_b0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10238-015-0345-6","article-title":"Autoimmune uveitis: clinical, pathogenetic, and therapeutic features","volume":"16","author":"Prete","year":"2016","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114903_b0045","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00417-022-05941-x","article-title":"Management of autoimmune retinopathy treated with intravitreal dexamethasone implant","volume":"261","author":"Hou","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114903_b0050","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/0002-9394(75)90687-X","article-title":"Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure","volume":"79","author":"Cantrill","year":"1975","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2025.114903_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173369","article-title":"Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model","volume":"884","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114903_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110171","article-title":"Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush","volume":"119","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114903_b0065","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.7150\/thno.26281","article-title":"Abnormal mTORC1 signaling leads to retinal pigment epithelium degeneration","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"issue":"1873-3441 (Electronic)","key":"10.1016\/j.ejpb.2025.114903_b0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.008","article-title":"Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation","volume":"143","author":"Ramsay","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114903_b0075","first-page":"659","article-title":"Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1\/Th2\/Th17 cells and upregulating CD4+ CD25+ Foxp3 regulatory T cells","volume":"8","author":"Yuan","year":"2015","journal-title":"International journal of ophthalmology"},{"issue":"1","key":"10.1016\/j.ejpb.2025.114903_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12348-010-0015-5","article-title":"A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis","volume":"1","author":"Phillips","year":"2011","journal-title":"Journal of Ophthalmic Inflammation and Infection"},{"issue":"1873\u20133476 (Electronic)","key":"10.1016\/j.ejpb.2025.114903_b0085","article-title":"The topical ocular delivery of rapamycin to posterior eye tissues and the suppression of retinal inflammatory disease","volume":"621","author":"Badr","year":"2022","journal-title":"Int J Pharmaceut"},{"issue":"1873\u20133476 (Electronic)","key":"10.1016\/j.ejpb.2025.114903_b0090","article-title":"Subconjunctival injection of rapamycin-loaded polymeric microparticles for effective suppression of noninfectious uveitis in rats","volume":"657","author":"Mo","year":"2024","journal-title":"Int J Pharmaceut"},{"issue":"1664-3224 (Electronic)","key":"10.1016\/j.ejpb.2025.114903_b0095","article-title":"Therapeutic effect of rapamycin-loaded small extracellular vesicles derived from mesenchymal stem cells on experimental autoimmune uveitis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114903_b0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2885.2008.00986.x","article-title":"Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses","volume":"31","author":"Douglas","year":"2008","journal-title":"J. Vet. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114903_b0105","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.ophtha.2018.06.015","article-title":"Intravitreal sirolimus for the treatment of noninfectious uveitis","volume":"125","author":"Nguyen","year":"2018","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ejpb.2025.114903_b0110","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: a Phase III sirolimus study assessing double-masked Uveitis treatment (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ejpb.2025.114903_b0115","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ophtha.2020.03.033","article-title":"Study Assessing double, Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) program","volume":"127","author":"Merrill","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ejpb.2025.114903_b0120","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.9.6.20","article-title":"Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in Rabbit eyes","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114903_b0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.molpharmaceut.0c00411","article-title":"Diffusion and protein corona formation of lipid-based nanoparticles in the vitreous humor: profiling and pharmacokinetic considerations","volume":"18","author":"Tavakoli","year":"2021","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114903_b0130","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.apsb.2021.10.022","article-title":"Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation","volume":"12","author":"Xia","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1549\u20139642 (Electronic)","key":"10.1016\/j.ejpb.2025.114903_b0135","article-title":"Synthetic high-density lipoprotein nanoparticles delivering rapamycin for the treatment of age-related macular degeneration","volume":"44","author":"Mei","year":"2022","journal-title":"Nanomedicine-Nanotechnology Biology and Medicine"},{"key":"10.1016\/j.ejpb.2025.114903_b0140","article-title":"Nanotherapeutics-mediated tolerogenic induction for enabling adeno-associated virus vector gene therapy re-administration by overcoming anti-drug antibodies","author":"Liu","year":"2025","journal-title":"Mater. Horiz."},{"issue":"12","key":"10.1016\/j.ejpb.2025.114903_b0145","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.biomaterials.2012.01.030","article-title":"The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection","volume":"33","author":"Koo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2025.114903_b0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-1-60761-720-4_22","article-title":"Rodent models of experimental autoimmune uveitis","volume":"900","author":"Agarwal","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114903_b0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.exer.2011.04.012","article-title":"Correlation of optical coherence tomography with clinical and histopathological findings in experimental autoimmune uveoretinitis","volume":"93","author":"Gadjanski","year":"2011","journal-title":"Exp. Eye Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:02:45Z","timestamp":1769810565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0939641125002802"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114903","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-assembled rapamycin prodrug nanoparticles for posterior segment targeting and effective treatment of experimental uveitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114903"}}